ESR1 and neoplasm: Despite these remarkable achievements, in general, clinicians still rely on traditional clinicopathologic features and readily available tumor markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).